Last updated on November 2018

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

Brief description of study

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.

Clinical Study Identifier: NCT03033511

Contact Investigators or Research Sites near you

Start Over


CHA Bundang Medical center, CHA University /ID# 161281
Seongnam-si, Korea, Republic of
  Connect »